BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Colombo M. Screening for Cancer in Viral Hepatitis. Clinics in Liver Disease 2001;5:109-22. [DOI: 10.1016/s1089-3261(05)70156-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Elsewify WAE, Hassan EA, Mekky MA, Abd El-Rehim ASE, Sayed ZEA, Abdel Malek MO, ElMelegy TTH, Sabry A. Usefulness of Circulating Methylated p16 as a Noninvasive Molecular Biomarker for Hepatitis C-Related Hepatocellular Carcinoma with Normal Serum Alpha-Fetoprotein Levels. Int J Gen Med 2020;13:147-55. [PMID: 32431531 DOI: 10.2147/IJGM.S249272] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Liu Y, Zhou R, Yuan X, Han N, Zhou S, Xu H, Guo M, Yu S, Zhang C, Yin T, Wu K. DACH1 is a novel predictive and prognostic biomarker in hepatocellular carcinoma as a negative regulator of Wnt/β-catenin signaling. Oncotarget 2015;6:8621-34. [PMID: 25940701 DOI: 10.18632/oncotarget.3281] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
3 Jin YJ, Aycheh HM, Han S, Chamberlin J, Shin J, Byun S, Lee Y. Differential alternative splicing between hepatocellular carcinoma with normal and elevated serum alpha-fetoprotein. BMC Med Genomics 2020;13:194. [PMID: 33371894 DOI: 10.1186/s12920-020-00836-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Macedo G, Lopes S, Barroso S, Costa-Maia J, de Matos N. Hepatocellular carcinoma in orthotopic liver transplantation candidates. Transplant Proc 2003;35:1113-4. [PMID: 12947879 DOI: 10.1016/s0041-1345(03)00329-4] [Reference Citation Analysis]
5 Quante M, Benckert C, Thelen A, Uhlmann D, Bartels M, Moche M, Dollinger M, Wittekind C, Jonas S. Liver transplantation to treat suspected hepatocellular carcinoma in iron-free foci in congenital hemochromatosis: case report. Transplant Proc 2011;43:2066-9. [PMID: 21693327 DOI: 10.1016/j.transproceed.2011.02.061] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
6 Brodeur CM, Thibault P, Durand M, Perreault JP, Bisaillon M. Dissecting the expression landscape of cytochromes P450 in hepatocellular carcinoma: towards novel molecular biomarkers. Genes Cancer 2019;10:97-108. [PMID: 31258835 DOI: 10.18632/genesandcancer.190] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
7 Bialecki ES, Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. HPB (Oxford). 2005;7:26-34. [PMID: 18333158 DOI: 10.1080/13651820410024049] [Cited by in Crossref: 132] [Cited by in F6Publishing: 125] [Article Influence: 11.0] [Reference Citation Analysis]
8 Meany DL, Sokoll LJ, Chan DW. Early Detection of Cancer: Immunoassays for Plasma Tumor Markers. Expert Opin Med Diagn. 2009;3:597-605. [PMID: 19966928 DOI: 10.1517/17530050903266830] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
9 Wong CR, Garcia RT, Trinh HN, Lam KD, Ha NB, Nguyen HA, Nguyen KK, Levitt BS, Nguyen MH. Adherence to screening for hepatocellular carcinoma among patients with cirrhosis or chronic hepatitis B in a community setting. Dig Dis Sci. 2009;54:2712-2721. [PMID: 19876735 DOI: 10.1007/s10620-009-1015-x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 3.2] [Reference Citation Analysis]
10 Kayar Y, Turkdogan KA, Baysal B, Unver N, Danalioglu A, Senturk H. EUS-guided FNA of a portal vein thrombus in hepatocellular carcinoma. Pan Afr Med J 2015;21:86. [PMID: 26491529 DOI: 10.11604/pamj.2015.21.86.6991] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
11 Zhao L, Mou DC, Peng JR, Huang L, Wu ZA, Leng XS. Diagnostic value of cancer-testis antigen mRNA in peripheral blood from hepatocellular carcinoma patients. World J Gastroenterol 2010; 16(32): 4072-4078 [PMID: 20731022 DOI: 10.3748/wjg.v16.i32.4072] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
12 Ahn KS, O'Brien DR, Kim YH, Kim TS, Yamada H, Park JW, Park SJ, Kim SH, Zhang C, Li H, Kang KJ, Roberts LR. Associations of Serum Tumor Biomarkers with Integrated Genomic and Clinical Characteristics of Hepatocellular Carcinoma. Liver Cancer 2021;10:593-605. [PMID: 34950182 DOI: 10.1159/000516957] [Reference Citation Analysis]
13 Yang M, Chen G, Dang Y, Luo D. Significance of decoy receptor 3 in sera of hepatocellular carcinoma patients. Ups J Med Sci. 2010;115:232-237. [PMID: 20977315 DOI: 10.3109/03009734.2010.516410] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
14 Krishnamurthy S, Gilot D, Ahn SB, Lam V, Shin JS, Guillemin GJ, Heng B. Involvement of Kynurenine Pathway in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5180. [PMID: 34680327 DOI: 10.3390/cancers13205180] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Teng W, Jeng WJ, Chen WT, Lin CC, Lin CY, Lin SM, Sheen IS. Soluble form of CTLA-4 is a good predictor for tumor recurrence after radiofrequency ablation in hepatocellular carcinoma patients. Cancer Med 2022. [PMID: 35435327 DOI: 10.1002/cam4.4760] [Reference Citation Analysis]
16 Yoon AR, Hong J, Kim M, Yun CO. Hepatocellular carcinoma-targeting oncolytic adenovirus overcomes hypoxic tumor microenvironment and effectively disperses through both central and peripheral tumor regions. Sci Rep 2018;8:2233. [PMID: 29396500 DOI: 10.1038/s41598-018-20268-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
17 Lu CY, Chen SY, Peng HL, Kan PY, Chang WC, Yen CJ. Cell-free methylation markers with diagnostic and prognostic potential in hepatocellular carcinoma. Oncotarget 2017;8:6406-18. [PMID: 28031532 DOI: 10.18632/oncotarget.14115] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
18 Trung NT, Hoan NX, Trung PQ, Binh MT, Van Tong H, Toan NL, Bang MH, Song LH. Clinical significance of combined circulating TERT promoter mutations and miR-122 expression for screening HBV-related hepatocellular carcinoma. Sci Rep 2020;10:8181. [PMID: 32424223 DOI: 10.1038/s41598-020-65213-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
19 Han EC, Ryoo SB, Park JW, Yi JW, Oh HK, Choe EK, Ha HK, Park BK, Moon SH, Jeong SY, Park KJ. Oncologic and surgical outcomes in colorectal cancer patients with liver cirrhosis: A propensity-matched study. PLoS One 2017;12:e0178920. [PMID: 28586376 DOI: 10.1371/journal.pone.0178920] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
20 Alunni-Fabbroni M, Rönsch K, Huber T, Cyran CC, Seidensticker M, Mayerle J, Pech M, Basu B, Verslype C, Benckert J, Malfertheiner P, Ricke J. Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial. J Transl Med 2019;17:328. [PMID: 31570105 DOI: 10.1186/s12967-019-2079-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
21 Pennisi G, Celsa C, Giammanco A, Spatola F, Petta S. The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives. Int J Mol Sci 2019;20:E5613. [PMID: 31717576 DOI: 10.3390/ijms20225613] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
22 Hu B, Tian X, Sun J, Meng X. Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma: a meta-analysis. Int J Mol Sci. 2013;14:23559-23580. [PMID: 24317431 DOI: 10.3390/ijms141223559] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 5.0] [Reference Citation Analysis]